SCHEIBLER LUKAS 4
4 · Apellis Pharmaceuticals, Inc. · Filed Dec 5, 2023
Insider Transaction Report
Form 4
SCHEIBLER LUKAS
See Remarks
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-12-01−10,000→ 39,391 totalExercise: $13.85Exp: 2029-02-07→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2023-12-01$13.85/sh+10,000$138,500→ 78,299 total - Sale
Common Stock
2023-12-01$60.00/sh−10,000$600,000→ 68,299 total
Footnotes (2)
- [F1]This is a scheduled exercise and sale from 10B5-1 trading plan.
- [F2]This represents a stock option grant made on 02/08/2019 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.